Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

6.29
+0.32005.36%
Post-market: 6.310.0200+0.32%19:37 EDT
Volume:1.00M
Turnover:6.21M
Market Cap:862.63M
PE:-1.64
High:6.30
Open:5.92
Low:5.85
Close:5.97
Loading ...

Stock Track | Vir Biotechnology Soars 5.83% as Cancer Drugs Show Promise

Stock Track
·
10 Jan

BUZZ-Morgan Stanley upgrades Vir Biotechnology on cancer drugs trial data

Reuters
·
10 Jan

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

Zacks
·
10 Jan

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Zacks
·
10 Jan

Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

TipRanks
·
09 Jan

Vir Biotechnology Is Maintained at Neutral by JP Morgan

Dow Jones
·
09 Jan

Morgan Stanley Upgrades Vir Biotechnology to Overweight From Equalweight, Adjusts Price Target to $20 From $10

MT Newswires Live
·
09 Jan

Vir Biotechnology (VIR) Gets a Buy from Barclays

TIPRANKS
·
09 Jan

U.S. RESEARCH ROUNDUP-Accolade, Costco Wholesale, RH

Reuters
·
09 Jan

Vir Biotechnology Inc : JP Morgan Raises Target Price to $14 From $10

THOMSON REUTERS
·
09 Jan

Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com

Dow Jones
·
09 Jan

Vir Biotechnology Up Over 65%, on Pace for Largest Percent Increase Since January 2021 -- Data Talk

Dow Jones
·
08 Jan

Vir Biotech Shares Rise on Positive Data for Cancer Treatments

Dow Jones
·
08 Jan

Vir Biotechnology Shares up 55.8% on Positive Data From Early-Stage Trials for Tumor Treatments

THOMSON REUTERS
·
08 Jan

BUZZ-Vir jumps on positive data from early-stage trials for tumor treatments

Reuters
·
08 Jan

BRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC

Reuters
·
08 Jan

Vir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials

TIPRANKS
·
08 Jan

Vir Biotechnology Shares up 31.7% Premarket After Early-Stage Trial Data for Prostate Cancer Treatment

THOMSON REUTERS
·
08 Jan

Vir Biotechnology Inc - No Dose-Limiting Crs Observed for Vir-5818 or Vir-5500

THOMSON REUTERS
·
08 Jan